CompletedNot Applicable

Breast Cancer Risk After Diagnostic Gene Sequencing

France, Germany405 participantsStarted 2019-10-22

Plain-language summary

Study of the psychological impact of breast cancer risk communication in Cancer Genetics based on the personalized estimation of the BOADICEA V5/PLUS model ("Breast and Ovarian Analysis of Disease Incidence and Carrier Estimation Algorithm-version 5 or PLUS").

Who can participate

Age range18 Years

SexFEMALE

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓. Healthy woman, relative of a family member first tested (index case) who received a positive genetic test result (presence of a BRCA1 or BRCA2 deleterious variant or a moderate-penetrance BC gene deleterious variant) ;
✓. Who accept BRIDGES gene panel testing and the breast cancer risk PRS;
✓. Aged 18 years or over with no upper limit;
✓. Able to give informed written consent in accordance with national/local regulations and procedures;
✓. Able to understand the questionnaire language of the participating genetic clinic.

Exclusion criteria

✕. Woman affected with BC, with recurrent BC, with metastatic BC, with an ovarian cancer (OC) or cancer of any other site;
✕. Aged under 18 years old;
✕. Unable to give informed written consent;
✕. Unable to understand the questionnaire language of the participating clinic;
✕. Unable to answer the questionnaire due to physical or cognitive disturbance

What they're measuring

Psychosocial Assessment in Hereditary Cancer questionnaire (PAHC).

Timeframe: Up to 6 months

Trial details

NCT IDNCT04145817

SponsorInstitut Curie

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2021-08-27

View on ClinicalTrials.gov More Genetic Predisposition to Disease trials